U.S. Markets close in 10 mins

  • S&P 500

    4,120.96
    -43.04 (-1.03%)
     

  • Dow 30

    33,955.34
    -201.35 (-0.59%)
     

  • Nasdaq

    11,927.04
    -186.75 (-1.54%)
     

  • Russell 2000

    1,943.93
    -28.68 (-1.45%)
     

  • Crude Oil

    78.48
    +1.34 (+1.74%)
     

  • Gold

    1,886.70
    +1.90 (+0.10%)
     

  • Silver

    22.32
    +0.14 (+0.64%)
     

  • EUR/USD

    1.0716
    -0.0015 (-0.1393%)
     

  • 10-Yr Bond

    3.6530
    -0.0210 (-0.57%)
     

  • Vix

    19.73
    +1.07 (+5.73%)
     

  • GBP/USD

    1.2069
    +0.0017 (+0.1448%)
     

  • USD/JPY

    131.4070
    +0.3350 (+0.2556%)
     

  • BTC-USD

    22,884.35
    -322.55 (-1.39%)
     

  • CMC Crypto 200

    527.13
    -9.77 (-1.82%)
     

  • FTSE 100

    7,885.17
    +20.46 (+0.26%)
     

  • Nikkei 225

    27,606.46
    -79.01 (-0.29%)
     

The Joint (JYNT) Buys Northern California Regional Developer Zone

Zacks Equity Research
·3 min read

The Joint Corp. JYNT recently announced that it has acquired regional developer rights for the Northern California region on Apr 1. The medical care facility provider acquired the rights for $2.4 million.

The company expects the region to hold 75 clinics, including its right to oversee 56 franchisee clinics, of which 36 are in the active development phase and 20 are currently operating. The overall demographic modeling of the region incorporates additional 19 sites for future development.

The latest acquisition is a strong move from JYNT to enhance its footprint in the Northern California region. This is expected to improve the company’s margin contribution in the franchisee business and support its sites in the region. The move will likely accelerate The Joint’s greenfield project growth.

The latest acquisition follows its Mar 17 deal to acquire the regional developer territory of Northern New Jersey. By 2023-end, the company aims to open a total of 1,000 clinics. It intends to achieve the target through new greenfield projects and franchise clinic openings. The company is currently present in 700 locations in the United States. It witnesses around 11 million patient visits per annum, which is expected to rise in the future.

While new greenfield projects boost the company’s bottom line in the long run, they suppress profits in the short run. The Zacks Consensus Estimate for earnings for the current year is pegged at 33 cents per share, indicating a decline of 31.3% year over year. The bottom line has witnessed two downward movements in the past 60 days against none in the opposite direction.

Price Performance

Shares of JYNT have declined 26% in the past year against a 37.3% rise of the industry it belongs to.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

Zacks Rank & Key Picks

The Joint currently has a Zacks Rank #4 (Sell). Some better-ranked stocks in the medical space include Humana Inc. HUM, UnitedHealth Group Incorporated UNH and NextGen Healthcare, Inc. NXGN, each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Headquartered in Louisville, KY, Humana is one of the largest healthcare plan providers in the United States. HUM’s acquisitions and dispositions, efficient capital deployment, and strong Medicaid business position it for long-term gains. Humana beat earnings estimates in each of the last four quarters, with the average being 3.1%.

UnitedHealth’s global business is witnessing a recovery in membership and revenue figures. UNH’s favorable government business and strong capital position are other positives. Based in Minnetonka, MN, UnitedHealth beat earnings estimates in each of the last four quarters, with the average being 8.4%.

Headquartered in Irvine, CA, NextGen Healthcare develops and markets healthcare information systems. The Zacks Consensus Estimate for NXGN’s bottom line for the current quarter is pegged at 99 cents per share, indicating an increase from the year-ago level. NextGen Healthcare beat earnings estimates in each of the last four quarters, with the average being 17.5%.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report

Humana Inc. (HUM) : Free Stock Analysis Report

The Joint Corp. (JYNT) : Free Stock Analysis Report

NEXTGEN HEALTHCARE, INC (NXGN) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Recommended Stories

  • Why Lumen Stock Is Falling Hard Today

    Shares of Lumen Technologies (NYSE: LUMN), a cloud connectivity and security solutions company, were plunging Wednesday after it reported its fourth-quarter results. The company actually beat Wall Street's consensus estimates for the quarter, but investors focused their attention on management's disappointing guidance. Lumen's non-GAAP earnings per share were down 15% from the year-ago quarter to $0.43, but that easily outpaced analysts' average estimate of $0.19 for the quarter.

  • Why Enphase Energy's Stock Popped Then Dropped Today

    Expectations for a slowdown in some of Enphase's business in the first quarter took the air out of the stock today.

  • Tesla’s ‘Master Plan 3’: What to expect from Elon Musk at Investor Day

    Yahoo Finance's Pras Subramanian joins the Live show to discuss the expectations for Tesla's 'Master Plan 3'.

  • Why Teva Pharmaceutical Stock Is Sliding Today

    Shares of Teva Pharmaceutical Industries (NYSE: TEVA) were sliding 5.4% lower as of 11:47 a.m. ET on Wednesday. The decline came after the drugmaker announced its 2022 full-year and fourth-quarter results. Teva reported fourth-quarter revenue of $3.88 billion, down 5% year over year.

  • Intel Is Making a Catastrophic Mistake

    Intel (NASDAQ: INTC) might have just had one of the worst years in the history of blue chip stocks. During the year it lost $9.4 billion in free cash flow and the stock price fell nearly 50%. An inventory glut in the semiconductor industry, especially in PC chips, hammered peers like Advanced Micro Devices and Micron Technology as well, and a decline in PC demand is also weighing on performance.

  • Disney earnings: Investors eye potential layoffs, Bob Iger’s tone

    Yahoo Finance’s Allie Canal joins the Live show to discuss the expectations for Disney earnings.

  • Cathie Wood's Investment Firm has Bought These 3 Stocks at Least 7 Days In a Row

    Cathie Wood has made quite a name for herself as the top growth stock picker at Ark Invest in recent years. Wood has spent the last seven trading days buying metal 3D printing company Velo3D , the past eight sessions buying human tissue 3D printing company Organovo , and the past nine sessions buying clinical-stage oncology treatment company Repare Therapeutics . In 2022, Wood acquired 10.1 million new shares of Velo3D worth about $32 million, according to Stock Circle, bringing her ownership of outstanding stock to 5.8%.

  • Why Alphabet Stock Plunged Today

    Shares of Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) were taking a dive today after the market reacted poorly to its AI event this morning. The biggest issue seemed to be that its new Bard AI technology, its competitor to OpenAI's ChatGPT, gave inaccurate information at the presentation. Alphabet's event this morning came just two days after it announced Bard AI in a blog post on Monday, and just a day after Microsoft unveiled its own ChatGPT-powered version of its Bing search engine, showing the race in AI-powered search is rapidly heating up.

  • 15 dividend stocks whose 5% to 10% yields appear safe in 2023 and 2024 by this analysis

    V.F., an S&P 500 Dividend Aristocrat, raised its payout for at least 25 straight years before cutting. Here's how to select dividend stocks for safety.

  • 2 of the Fastest-Growing Stocks to Buy Now

    Overall, economic growth has slowed down over the past year or so, and many businesses are suffering as a result. In fact, some well-established businesses with clear paths to profitability are still growing at annualized rates of 50% or more -- and here are two that look especially promising. In the latest quarter, CrowdStrike's revenue grew 53% year over year despite the challenging economic climate, and while the company isn't consistently profitable yet on its bottom line, it is generating more free cash flow than ever before.

  • Kiora’s stock rallies as eye drop treatment moves into mid-stage clinical trial

    MARKET PULSE Shares of Kiora Pharmaceuticals Inc. (KPRX) soared about 57% in premarket trading on Tuesday after the company said it will begin a Phase 2 clinical trial for its experimental eye drops as a treatment for ocular rheumatoid arthritis.

  • Lumen stock plunges toward levels not seen in 34 years amid a ‘reset’

    The telecommunications company pressed the reset button and disappointed Wall Street with its outlook in a Tuesday afternoon report

  • Better AI Stock: C3.ai vs. Palantir Technologies

    C3.ai (NYSE: AI) and Palantir (NYSE: PLTR) represent two different plays on the secular growth of the enterprise AI software market. C3 develops AI algorithms that can be integrated into an organization's existing software to automate tasks, improve employee safety, cut costs, and detect fraud. Palantir's platform accumulates large amounts of information from disparate sources to help organizations make better data-driven decisions.

  • Google Stock Tumbles 8% After Its Bard AI Ad Shows Inaccurate Answer

    Google stock tumbled early Wednesday after an ad for the company's new Bard service showed the AI chatbot offering an inaccurate answer.

  • Google Facing Criticism After AI Bot Bard Makes Factual Error During First Demo

    Microsoft's Bing search engine is using ChatGPT to enhance its search results and Google has responded with AI technology of its own.

  • Why Capri Holdings Stock Dropped Like a Rock Today

    Shares of luxury fashion company Capri Holdings (NYSE: CPRI) dropped like a rock on Wednesday after the company delivered quarterly results and financial guidance that fell short of Wall Street's expectations. As of 10:30 a.m. ET, Capri Holdings stock was down by a whopping 25%, pushing it below where it was trading exactly 10 years ago. Wall Street's reaction to Capri Holdings' results for its fiscal 2023 third quarter looks a little extreme when considering its top-line figure.

  • Why Compass Minerals International Stock Is Sinking Today

    Shares of Compass Minerals International (NYSE: CMP) had tumbled nearly 13% at 10:30 a.m. ET on Wednesday. Compass Minerals International got "off to a mixed start" in its fiscal year, according to comments by CEO Kevin Crutchfield in the earnings press release. While results improved in its salt division, weak demand in its plant nutrition segment and cost pressures hurt its financial results.

  • AI competition: Google’s Bard vs. Microsoft’s Bing-ChatGPT crossover

    Yahoo Finance's Allie Garfinkle explains the generative AI search wars as competition heats up between Google and Microsoft.

  • ‘I really need help.’ I have $580K in retirement savings, but can’t find a financial adviser because the ones I spoke to want clients to be richer than me. What should I do?

    Question: I’m in Maryland and could use a financial planner for my Roth IRA and my TSP [a retirement savings plan for government employees] to make investment suggestions and help manage my funds to improve returns. My Roth IRA is about $80,000 and I really need help finding the right investments to grow this account in this terrible environment. “Not all financial planners require a minimum number of assets to work with you,” says certified financial planner Jonathan Grannick of Wonder Wealth.

  • Here's Why New Relic Stock Jumped Higher Today

    Shares of enterprise-software company New Relic (NYSE: NEWR) jumped on Wednesday after it reported financial results for the third quarter of its fiscal 2023. Adjusted profits came in much higher than Wall Street expected, and that's a leading reason New Relic stock was up 20% as of 11:40 a.m. ET. New Relic's management had guided for Q3 revenue of up to $235 million.